Back to Journals » OncoTargets and Therapy » Volume 10

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia

Authors Huber H, Edenhofer S, Estenfelder S, Stilgenbauer S

Received 30 August 2016

Accepted for publication 15 November 2016

Published 7 February 2017 Volume 2017:10 Pages 645—656

DOI https://doi.org/10.2147/OTT.S102646

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 3

Editor who approved publication: Dr XuYu Yang

Henriette Huber, Simone Edenhofer, Sven Estenfelder, Stephan Stilgenbauer

Department of Internal Medicine III, Ulm University, Ulm, Germany

Abstract: Over the last few years, dramatic changes have occurred in the treatment of chronic lymphocytic leukemia (CLL). The current standard for young and fit patients with CLL remains chemoimmunotherapy, namely the fludarabine, cyclophosphamide, and rituximab (FCR) regimen. However, novel oral therapies are presently being introduced and represent a considerable breakthrough concerning effectiveness and safety profile. In particular, the very high-risk group of CLL patients, defined by the genetic aberration del(17p) and/or TP53 mutation, benefit from the new agents. These genetic abnormalities are the most relevant negative prognostic markers in the context of chemoimmunotherapy. New targeted therapies allow different approaches to improve outcomes.

Keywords: CLL, del(17p), TP53, BCL-2, venetoclax

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]